Compare Nuwellis Inc (NUWE) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs SAP SE — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while SAP SE trades at $214.78 (market cap $238.67B). The key difference: SAP SE is far larger — about 108486.4× Nuwellis Inc's market cap, and SAP SE pays a 1.38% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and SAP SE for 118 Days on average.
| NUWE | SAP | |
|---|---|---|
Market Cap | $2.20M | $238.67B |
Volume | 121,544 | 2,252,662 |
Sector | Health | Technology |
52-Week High | $146.65 | $280.46 |
52-Week Low | $0.68 | $146.38 |
Typical Hold Time | 26 Days | 118 Days |
Enterprise Value | -$1.52M | $237.42B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
SAP trades at $212.4, up 1.08% today, with a bullish technical signal and strong fundamentals. Revenue grew to $36.8B in 2025, with net income of $7.16B and a 20.41% margin. Recent earnings show mixed results, beating in Q4 2025 and Q1 2026 but missing in Q2 2026. Analyst consensus is a Buy with a $253.40 price target. Cloud revenue growth and AI initiatives are key drivers, though competition and margin pressures pose risks.
The outlook is positive, supported by robust cash flow and a €10B buyback program. Upside potential exists if AI and cloud strategies deliver, but execution risks and market volatility could hinder gains. Investors should weigh strong profitability against sector headwinds and valuation multiples above industry averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
